State of Alaska Department of Revenue Has $849,000 Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Alaska Department of Revenue lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,838 shares of the biopharmaceutical company’s stock after purchasing an additional 995 shares during the period. State of Alaska Department of Revenue’s holdings in Halozyme Therapeutics were worth $849,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Whittier Trust Co. acquired a new position in Halozyme Therapeutics in the 1st quarter valued at about $27,000. GAMMA Investing LLC grew its stake in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 254 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at about $49,000. Finally, Fidelis Capital Partners LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at about $52,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HALO has been the topic of a number of research reports. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Benchmark restated a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. The Goldman Sachs Group increased their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $40,063,244.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $40,063,244.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now directly owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 in the last quarter. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $58.72 on Wednesday. The company has a 50 day moving average of $56.83 and a 200-day moving average of $52.42. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company has a market cap of $7.44 billion, a PE ratio of 19.44, a price-to-earnings-growth ratio of 0.50 and a beta of 1.29.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.68 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.1 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.